Fig. 3From: Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysisORR rate in IDH-mutant AML patients treated with IDH inhibitors. A Newly diagnosed AML patients treated with IDH inhibitors; B Newly diagnosed AML patients treated with IDH inhibitors in combination; C Newly diagnosed AML patients treated with IDH inhibitors alone; D Relapsed or refractory AML patients treated with IDH inhibitors. ORR overall response, AML acute myeloid leukemia, IDH isocitrate dehydrogenase genes, 95% CI 95% confidence intervalBack to article page